Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 38Lung Neoplasms 29Carcinoma, Non-Small-Cell Lung 28Neoplasms 16Uterine Cervical Neoplasms 13Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 10Carcinoma, Hepatocellular 10Sarcoma 9Rectal Neoplasms 9Carcinoma, Renal Cell 9Prostatic Neoplasms 8Neoplasm Metastasis 8Melanoma 8Lymphoma 8Glioblastoma 8Colorectal Neoplasms 8Brain Neoplasms 8Thyroid Neoplasms 7Stomach Neoplasms 7Solid Tumor 7Pancreatic Neoplasms 7Oropharyngeal Neoplasms 7Multiple Myeloma 7Head and Neck Neoplasms 7Colonic Neoplasms 7Urinary Bladder Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Hodgkin Disease 6Breast Neoplasms, Male 6

Interventions

lutetium Lu 177 dotatate 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Lung Neuroendocrine Tumor × Fluorodeoxyglucose F18 × Clear all
NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡